S. 350 117th Congress
Newborn Screening Saves Lives Reauthorization Act of 2021
Latest action, Feb 22, 2021: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
14 cosponsors
Sponsored by Margaret Wood Hassan (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
11 D · 3 R
- Democrat
- Republican
- Independent
Referred to: Senate: Health, Education, Labor, and Pensions Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
AMERICAN COLLEGE OF MEDICAL GENETICS
KING & SPALDING LLP
8 reports
8 reports
8 reports
8 reports
TRAVERE THERAPEUTICS
ALSTON & BIRD LLP
8 reports
8 reports
BIOMARIN PHARMACEUTICAL INC.
CHAMBER HILL STRATEGIES
7 reports
RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES)
7 reports
6 reports
6 reports
5 reports
5 reports
CAE USA INC.
5 reports
CAE USA, INC
ALPINE GROUP PARTNERS, LLC.
5 reports
All 25 of 30 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AMERICAN COLLEGE OF MEDICAL GENETICS | KING & SPALDING LLP | 8 | $160K | Q1 2021 | Q3 2022 | yes |
| MARCH OF DIMES | 8 | $550K | Q1 2021 | Q3 2022 | yes | |
| MUSCULAR DYSTROPHY ASSOCIATION, INC. | 8 | $1.1M | Q1 2021 | Q3 2022 | yes | |
| TAKEDA PHARMACEUTICALS AMERICA INC | 8 | $9.4M | Q1 2021 | Q3 2022 | yes | |
| TRAVERE THERAPEUTICS | ALSTON & BIRD LLP | 8 | $0 | Q1 2021 | Q3 2022 | yes |
| TRAVERE THERAPEUTICS | 8 | $1.3M | Q1 2021 | Q3 2022 | yes | |
| AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS | 7 | $916K | Q4 2021 | Q3 2022 | yes | |
| BIOMARIN PHARMACEUTICAL INC. | CHAMBER HILL STRATEGIES | 7 | $0 | Q4 2021 | Q3 2022 | yes |
| RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES) | 7 | $140K | Q4 2021 | Q3 2022 | yes | |
| ASTRAZENECA PHARMACEUTICALS LP | 6 | $7.2M | Q4 2021 | Q3 2022 | yes | |
| CYSTIC FIBROSIS FOUNDATION | 6 | $630K | Q1 2021 | Q3 2022 | yes | |
| AMERICAN ACADEMY OF PEDIATRICS | 5 | $1.2M | Q4 2021 | Q3 2022 | yes | |
| BIOMARIN PHARMACEUTICAL INC. | 5 | $1.2M | Q4 2021 | Q3 2022 | yes | |
| CAE USA INC. | 5 | $620K | Q4 2021 | Q3 2022 | yes | |
| CAE USA, INC | ALPINE GROUP PARTNERS, LLC. | 5 | $300K | Q4 2021 | Q3 2022 | yes |
| AMERICAN SOCIETY OF HEMATOLOGY | 4 | $120K | Q1 2022 | Q3 2022 | yes | |
| NATIONAL ASSOCIATION OF PEDIATRIC NURSE PRACTITIONERS | MASON CONSULTING, LLC | 4 | $96K | Q1 2022 | Q3 2022 | yes |
| AEGLEA BIOTHERAPEUTICS, INC. | THE KPM GROUP DC LLC | 3 | $90K | Q1 2021 | Q3 2021 | yes |
| RARE DISEASE COMPANY COALITION | THE KPM GROUP DC LLC | 3 | $90K | Q4 2021 | Q3 2021 | yes |
| THE MENDED HEARTS, INC. | CURA STRATEGIES | 3 | $47K | Q4 2022 | Q3 2022 | yes |
| ULTRAGENYX PHARMACEUTICAL | THE KPM GROUP DC LLC | 3 | $145K | Q1 2021 | Q3 2021 | yes |
| ALEXION PHARMACEUTICALS, INC. | 2 | $430K | Q2 2021 | Q3 2021 | yes | |
| ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC) | 2 | $170K | Q1 2021 | Q3 2022 | yes | |
| CEDARS-SINAI MEDICAL CENTER | 2 | $230K | Q2 2022 | Q3 2022 | yes | |
| CHIESI USA, INC. | THE KPM GROUP DC LLC | 2 | $0 | Q4 2021 | Q1 2022 | yes |